Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saruparib in Advanced/Recurrent Ovarian Cancer (Ovarian Platform)
NCT07060365Phase 2Withdrawn
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of saruparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AstraZeneca. Planned start Sep 2025; status: withdrawn.
02
Drugs
saruparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07060365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07060365.